keyword
MENU ▼
Read by QxMD icon Read
search

anthracycline induced cardiomyopathy

keyword
https://www.readbyqxmd.com/read/29716714/evaluation-of-a-polymorphism-in-mybpc3-in-patients-with-anthracycline-induced-cardiotoxicity
#1
M Thirumalai Vinodhini, S Sneha, R P Nagare, S Bindhya, V Shetty, D Manikandan, P Ganesan, T G Sagar, T S Ganesan
Cardiotoxicity is the most serious side effect of anthracyclines (doxorubicin, daunorubicin or epirubicin). The incidence of anthracycline induced late cardiac toxicity (AIC) that is overt clinically is 3-5% in the Indian population. Polymorphism in intron 32 (deletion of 25bp) of MYBPC3 has been shown to be present exclusively in Asians and more so in South India (3-8%). The frequency of the polymorphism is significantly higher (13%) in patients with cardiomyopathy in India. Fifteen patients were identified to have cardiac dysfunction following treatment for malignant lymphoma with doxorubicin containing regimens...
March 2018: Indian Heart Journal
https://www.readbyqxmd.com/read/29698683/anticancer-drug-induced-cardiac-rhythm-disorders-current-knowledge-and-basic-underlying-mechanisms
#2
REVIEW
Joachim Alexandre, Javid Moslehi, Kevin R Bersell, Christian Funck-Brentano, Dan M Roden, Joe-Elie Salem
Significant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases. Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy. Much attention has focused on heart failure; however, other cardiotoxicities, notably cardiac rhythm disorders, can occur without underlying cardiomyopathy...
April 24, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29673122/native-myocardial-t1-time-can-predict-development-of-subsequent-anthracycline-induced-cardiomyopathy
#3
Fabian Muehlberg, Stephanie Funk, Leonora Zange, Florian von Knobelsdorff-Brenkenhoff, Edyta Blaszczyk, Alexander Schulz, Saeed Ghani, Annete Reichardt, Peter Reichardt, Jeanette Schulz-Menger
AIMS: This study aims to assess subclinical changes in functional and morphological myocardial magnetic resonance parameters very early into an anthracycline treatment, which may predict subsequent development of anthracycline-induced cardiomyopathy (aCMP). METHODS AND RESULTS: Thirty sarcoma patients with planned anthracycline-based chemotherapy (360-400 mg/m2 doxorubicin-equivalent) were recruited. Median treatment time was 19.1 ± 2.1 weeks. Enrolled individuals received three cardiovascular magnetic resonance studies (before treatment, 48 h after first anthracycline treatment, and upon completion of treatment)...
April 19, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29552206/protective-effect-of-berberine-on-acute-cardiomyopathy-associated-with-doxorubicin-treatment
#4
Chen Xiong, Yan-Zhao Wu, Yu Zhang, Zi-Xiao Wu, Xue-Yan Chen, Ping Jiang, Hui-Cai Guo, Ke-Rang Xie, Ke-Xin Wang, Su-Wen Su
Doxorubicin (DOX) is a potent and broad-spectrum anthracycline chemotherapeutic agent, but dose-dependent cardiotoxic side effects limit its clinical application. This toxicity is closely associated with the generation of reactive oxygen species (ROS) radical during DOX metabolism. The present study investigated the effects of Berberine (Ber) on DOX-induced acute cardiac injury in a rat model and analysed its mechanism in cardiomyocytes in vitro . Serum creatine kinase (CK), creatine kinase isoenzyme (CK-MB) and malondialdehyde (MDA) levels were significantly increased in the DOX group compared with the control group...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29534446/chemotherapeutic-induced-cardiovascular-dysfunction-physiological-effects-early-detection-the-role-of-telomerase-to-counteract-mitochondrial-defects-and-oxidative-stress
#5
REVIEW
Nabeel Quryshi, Laura E Norwood Toro, Karima Ait-Aissa, Amanda Kong, Andreas M Beyer
Although chemotherapeutics can be highly effective at targeting malignancies, their ability to trigger cardiovascular morbidity is clinically significant. Chemotherapy can adversely affect cardiovascular physiology, resulting in the development of cardiomyopathy, heart failure and microvascular defects. Specifically, anthracyclines are known to cause an excessive buildup of free radical species and mitochondrial DNA damage (mt DNA) that can lead to oxidative stress-induced cardiovascular apoptosis. Therefore, oncologists and cardiologists maintain a network of communication when dealing with patients during treatment in order to treat and prevent chemotherapy-induced cardiovascular damage; however, there is a need to discover more accurate biomarkers and therapeutics to combat and predict the onset of cardiovascular side effects...
March 10, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29493056/anthracycline-induced-cardiomyopathy-secrets-and-lies
#6
EDITORIAL
Dimitrios Farmakis, Marina Mantzourani, Gerasimos Filippatos
No abstract text is available yet for this article.
May 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29458045/aldose-reductase-inhibitor-fidarestat-prevents-doxorubicin-induced-endothelial-cell-death-and-dysfunction
#7
Himangshu Sonowal, Pabitra Pal, Kirtikar Shukla, Ashish Saxena, Satish K Srivastava, Kota V Ramana
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better adjuvant therapies are warranted to improve the chemotherapeutic efficacy and to decrease cardiotoxicity. We have recently shown that aldose reductase inhibitor, fidarestat, increases the Dox-induced colon cancer cell death and reduces cardiomyopathy...
April 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29397400/cell-death-mechanisms-of-the-anti-cancer-drug-etoposide-on-human-cardiomyocytes-isolated-from-pluripotent-stem-cells
#8
Harshal Nemade, Umesh Chaudhari, Aviseka Acharya, Jürgen Hescheler, Jan Georg Hengstler, Symeon Papadopoulos, Agapios Sachinidis
Etoposide (ETP) and anthracyclines are applied for wide anti-cancer treatments. However, the ETP-induced cardiotoxicity remains to be a major safety issue and the underlying cardiotoxic mechanisms are not well understood. This study is aiming to unravel the cardiotoxicity profile of ETP in comparison to anthracyclines using physiologically relevant human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs). Using xCELLigence real-time cell analyser (RTCA), we found that single high dose of ETP induces irreversible increase in hPSC-CMs beating rate and decrease in beating amplitude...
April 2018: Archives of Toxicology
https://www.readbyqxmd.com/read/29385562/expression-profiling-of-human-pluripotent-stem-cell-derived-cardiomyocytes-exposed-to-doxorubicin-integration-and-visualization-of-multi-omics-data
#9
Gustav Holmgren, Peter Sartipy, Christian X Andersson, Anders Lindahl, Jane Synnergren
Anthracyclines, such as doxorubicin, are highly efficient chemotherapeutic agents against a variety of cancers. However, anthracyclines are also among the most cardiotoxic therapeutic drugs presently on the market. Chemotherapeutic-induced cardiomyopathy is one of the leading causes of disease and mortality in cancer survivors. The exact mechanisms responsible for doxorubicin-induced cardiomyopathy are not completely known, but the fact that the cardiotoxicity is dose-dependent and that there is a variation in time-to-onset of toxicity, and gender- and age differences suggests that several mechanisms may be involved...
January 27, 2018: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/29377985/cancer-therapy-induced-cardiomyopathy-can-human-induced-pluripotent-stem-cell-modelling-help-prevent-it
#10
Jonathan P Stack, Javid Moslehi, Nazish Sayed, Joseph C Wu
Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies...
January 25, 2018: European Heart Journal
https://www.readbyqxmd.com/read/29198224/case-report-and-review-of-the-literature-the-utilisation-of-a-ventricular-assist-device-as-bridge-to-recovery-for-anthracycline-induced-ventricular-dysfunction
#11
Diane Krasnopero, Alfred Asante-Korang, Jeffrey Jacobs, Stacie Stapleton, Jennifer Carapellucci, Mathew Dotson, Gary Stapleton
Ventricular assist devices are used in children with heart failure as a bridge to myocardial recovery or cardiac transplantation. Anthracyclines cause cardiac toxicity and may result in acute or long-term cardiac failure. We describe the use of a ventricular assist device as a bridge to recovery in a child with severe acute anthracycline-induced cardiomyopathy, and we review the associated literature. A 6-year-old girl was treated for acute myeloblastic leukaemia with daunorubicin and mitoxantrone. After 2 weeks her final dose of chemotherapy, her Left Ventricular Ejection Fraction decreased to 21%...
March 2018: Cardiology in the Young
https://www.readbyqxmd.com/read/29148208/comparison-of-long-term-outcome-in-anthracycline-related-versus-idiopathic-dilated-cardiomyopathy-a-single-centre-experience
#12
Alessandra Fornaro, Iacopo Olivotto, Luigi Rigacci, Mauro Ciaccheri, Benedetta Tomberli, Cecilia Ferrantini, Raffaele Coppini, Francesca Girolami, Francesco Mazzarotto, Marco Chiostri, Massimo Milli, Niccolò Marchionni, Gabriele Castelli
AIMS: Cardiac dysfunction is a severe complication of anthracycline-containing anticancer therapy. The outcome of anthracycline-induced cardiomyopathy (AICM) compared with other non-ischaemic causes of heart failure (HF), such as idiopathic dilated cardiomyopathy (IDCM), is unresolved. The aim of this study was to compare the survival of AICM patients with an IDCM cohort followed at our centre from 1990 to 2016. METHODS AND RESULTS: We included 67 patients (67% female, 50 ± 15 years) with AICM, defined as onset of otherwise unexplained left ventricular ejection fraction (LVEF) ≤50% following anthracycline therapy, and 488 IDCM patients (28% female, 55 ± 12 years)...
November 16, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29131861/delivery-of-epirubicin-via-slow-infusion-as-a-strategy-to-mitigate-chemotherapy-induced-cardiotoxicity
#13
Fang Yang, Qiao Lei, Lu Li, Jian Chang He, Jiajia Zeng, Chunxiang Luo, Sai-Ching Jim Yeung, Runxiang Yang
BACKGROUND: Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy. DESIGN AND METHODS: Healthy rats were randomized into groups: epirubicin (8 mg/kg) delivered intraperitoneally via micro osmotic pumps (MOP), epirubicin (8 mg/kg) by intraperitoneal (IP) bolus injection, and placebo control...
2017: PloS One
https://www.readbyqxmd.com/read/29098619/the-positive-effects-of-exercise-in-chemotherapy-related-cardiomyopathy
#14
Elena Cavarretta, Giorgio Mastroiacovo, Annik Lupieri, Giacomo Frati, Mariangela Peruzzi
Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2%, with a mortality rate over 60% at 2 years...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29019935/cardiotoxic-effects-of-short-term-doxorubicin-administration-involvement-of-connexin-43-in-calcium-impairment
#15
Michela Pecoraro, Antonio Rodríguez-Sinovas, Stefania Marzocco, Michele Ciccarelli, Guido Iaccarino, Aldo Pinto, Ada Popolo
The use of Doxorubicin (DOXO), a potent antineoplastic agent, is limited by the development of cardiotoxicity. DOXO-induced cardiotoxicity is multifactorial, although alterations in calcium homeostasis, seem to be involved. Since even the Connexin43 (Cx43) plays a pivotal role in these two phenomena, in this study we have analyzed the effects of DOXO on Cx43 expression and localization. Damage caused by anthracyclines on cardiomyocytes is immediate after each injection, in the present study we used a short-term model of DOXO-induced cardiomyopathy...
October 11, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28887671/histamine-2-receptor-antagonism-elicits-protection-against-doxorubicin-induced-cardiotoxicity-in-rodent-model
#16
Sundar Kumar Kondru, Ajay Godwin Potnuri, Lingesh Allakonda, Prasad Konduri
Doxorubicin (DOX), an anthracycline-based antibiotic, is regularly used in the management of carcinomas, and haematological malignancies have been downplayed in chemotherapy because of its ability to induce dilated cardiomyopathy (DCM). Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects. Redox imbalance and reactive oxygen species generation plays major role in DOX-induced cardiotoxicity. Histamine, known to mediate various cardiovascular effects, but nevertheless the role of histamine or its receptors in DOX-induced DCM is remained obscure...
April 2018: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28837153/cardioprotective-effects-of-fibroblast-growth-factor-21-against-doxorubicin-induced-toxicity-via-the-sirt1-lkb1-ampk-pathway
#17
Shudong Wang, Yonggang Wang, Zhiguo Zhang, Quan Liu, Junlian Gu
Doxorubicin (DOX) is a highly effective antineoplastic anthracycline drug; however, the adverse effect of the cardiotoxicity has limited its widespread application. Fibroblast growth factor 21 (FGF21), as a well-known regulator of glucose and lipid metabolism, was recently shown to exert cardioprotective effects. The aim of this study was to investigate the possible protective effects of FGF21 against DOX-induced cardiomyopathy. We preliminarily established DOX-induced cardiotoxicity models in H9c2 cells, adult mouse cardiomyocytes, and 129S1/SyImJ mice, which clearly showed cardiac dysfunction and myocardial collagen accumulation accompanying by inflammatory, oxidative stress, and apoptotic damage...
August 24, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28780919/anthracycline-induced-cardiotoxicity-in-patients-with-paediatric-bone-sarcoma-and-soft-tissue-sarcoma
#18
Ilaria Bini, Sebastian D Asaftei, Chiara Riggi, Elisa Tirtei, Rosaria Manicone, Eleonora Biasin, Maria Eleonora Basso, Gabriella Agnoletti, Franca Fagioli
OBJECTIVES: Anthracycline cardiotoxicity is an important side-effect in long-term childhood cancer survivors. We evaluated the incidence of and factors associated with anthracycline cardiotoxicity in a population of patients diagnosed with bone or soft tissue sarcoma. Materials and methods We retrospectively enrolled patients diagnosed with bone or soft tissue sarcoma, from 1995 to 2011, treated with anthracycline chemotherapy at our Centre and with a follow-up echocardiography carried out ⩾3 years from cardiotoxic therapy completion...
November 2017: Cardiology in the Young
https://www.readbyqxmd.com/read/28733066/effective-use-of-levosimendan-in-anthracycline-induced-cardiomyopathy-a-case-report
#19
Nikolaos Miaris, Stefanos Zezas, Joseph Sgouros, Dimitra-Christina Zirou, Stefania Gkoura, George Stamoulis, Helen Angelopoulou, George Avgeropoulos, Epaminondas Samantas
BACKGROUND: Anthracycline-induced cardiomyopathy is a serious side effect that ranges from mild left ventricular systolic impairment to congestive heart failure and cardiogenic shock. Currently, there is no evidence indicating the effective use of levosimendan in these cases. OBJECTIVE: We aim to present a case of life-threatening doxorubicin-induced cardiomyopathy that was successfully managed with levosimendan. CASE: A 48-year-old female with formerly normal heart function, who had been treated with doxorubicin-based regimens for dedifferentiated chondrosarcoma, presented with cardiomyopathy with low left ventricular ejection fraction eight months after the last infusion...
September 2017: Heart & Lung: the Journal of Critical Care
https://www.readbyqxmd.com/read/28700019/assessment-of-subclinical-doxorubicin-induced-cardiotoxicity-in-a-rat-model-by-speckle-tracking-imaging
#20
Yu Kang, Wei Wang, Hang Zhao, Zhiqing Qiao, Xuedong Shen, Ben He
Backgrounds: Despite their clear therapeutic benefits, anthracycline-induced cardiotoxicity is a major concern limiting the ability to reduce morbidity and mortality associated with cancers. The early identification of anthracycline-induced cardiotoxicity is of vital importance to assess the cardiac risk against the potential cancer treatment. Objective: To investigate whether speckle-tracking analysis can provide a sensitive and accurate measurement when detecting doxorubicin-induced left ventricular injury...
July 10, 2017: Arquivos Brasileiros de Cardiologia
keyword
keyword
56258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"